Search results for "VERSUS-HOST-DISEASE"

showing 5 items of 5 documents

Interleukin-22 in Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation

2016

International audience; Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment for hematologic malignancies and non-malignant diseases. Because of the lower toxicity of reduced intensity conditioning, the number of transplants is in constant increase. However, allo-HSCT is still limited by complications, such as graft-versus-host disease (GVHD), which is associated with important morbidity and mortality. Acute GVHD is an exacerbated inflammatory response that leads to the destruction of healthy host tissues by donor immune cells. Recently, the contribution of innate immunity in GVHD triggering has been investigated by several groups and resulted in …

0301 basic medicinelcsh:Immunologic diseases. Allergy[SDV.IMM] Life Sciences [q-bio]/Immunologyalloreactivitymedicine.medical_treatmentImmunologyInflammationchemical and pharmacologic phenomenaHematopoietic stem cell transplantationReviewBiologyInterleukin 2203 medical and health sciencesgraft-versus-host-disease0302 clinical medicineImmune systemimmune system diseasesallogeneic stem cell transplantationmedicinegraft-versus-host diseaseImmunology and AllergyInflammationInnate immune systeminterleukin-22medicine.disease3. Good healthTransplantation030104 developmental biologyGraft-versus-host diseasesurgical procedures operativeImmunology[SDV.IMM]Life Sciences [q-bio]/Immunologymedicine.symptomStem celllcsh:RC581-607030215 immunology
researchProduct

Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.

2015

Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell-derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti-tumour therapy, (b) pathogen vaccination, (c) immune-modulatory and regenerative therapies and (d) drug delivery. The translation of EVs into clinical therapies requires the categorization of EV-based therapeutics …

Bioquímica clínicaMedizinISCHEMIA-REPERFUSION INJURYBioinformaticsimmunology; neurobiology; haematology; stem cells; tissue regeneration; tumour vaccination; regulationimmunology0302 clinical medicineClinical trialsClinical investigationVERSUS-HOST-DISEASEMedicine and Health SciencesFIELD-FLOW FRACTIONATIONMedicineImmunologiahaematology; immunology; neurobiology; regulation; stem cells; tissue regeneration; tumour vaccinationmedia_common0303 health scienceslcsh:CytologyOUTER-MEMBRANE VESICLESneurobiologyregulationHematologyBiologia experimental3. Good healthTUMOR-DERIVED EXOSOMES030220 oncology & carcinogenesistumour vaccinationDrug deliveryhaematologyPosition PaperCèl·lules mareNeurobiologiaHistologyMedicina InvestigacióCèl·lulesNANOPARTICLE TRACKING ANALYSIStissue regenerationExtracellular vesiclesMESENCHYMAL STEM-CELLS03 medical and health sciencesstem cellsJournal Articlemedia_common.cataloged_instanceREGULATORY T-CELLSEuropean unionlcsh:QH573-671ENDOTHELIAL PROGENITOR CELLSHematologia030304 developmental biologybusiness.industryCell BiologyMicrovesiclesClinical trialPosition paperPharmaceutical manufacturingUMBILICAL-CORD BLOODbusinessNeuroscienceAssaigs clínics
researchProduct

Oral verruciform xanthoma and erythroplakia associated with chronic graft-versus-host disease: A rare case report and review of the literature

2017

Abstract Background Oral verruciform xanthoma is an uncommon benign lesion. Although oral verruciform xanthoma occurs in healthy individuals, it has been also reported in association with some inflammatory conditions. The aim of this study is to report a case of oral verruciform xanthoma associated with chronic graft-versus-host disease and to review the literature on this topic. Case presentation A 47-year-old Caucasian male presented to the Sector of Oral Medicine “V. Margiotta”, University Policlinic “P. Giaccone” of Palermo complaining of a mass on the gingiva. He first noticed the painless mass 1 year ago. He reported to have undergone allogenic hematopoietic stem cell transplantation …

Genetics and Molecular Biology (all)MaleVerruciform xanthomaBiopsylcsh:MedicineGraft vs Host DiseaseCase ReportBiochemistryChronic graft versus-host-disease; Erythroplakia; Oral potential malignant disorder; Verruciform xanthoma; Biochemistry Genetics and Molecular Biology (all)030207 dermatology & venereal diseases0302 clinical medicinelcsh:QH301-705.5Verruciform xanthomaErythroplakiamedicine.diagnostic_testChronic graft versus-host-diseaseHematopoietic Stem Cell TransplantationMED/28 - MALATTIE ODONTOSTOMATOLOGICHEGeneral MedicineMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.anatomical_structure030220 oncology & carcinogenesisOral erythroplakiamedicine.symptommedicine.medical_specialtyGeneral Biochemistry Genetics and Molecular BiologyOral potential malignant disorder03 medical and health sciencesTongueBiopsymedicineXanthomatosisLS7_3Humanslcsh:Science (General)Biochemistry Genetics and Molecular Biology (all)business.industrylcsh:RAmbientaleNodule (medicine)medicine.diseaseDermatologystomatognathic diseaseslcsh:Biology (General)ErythroplasiaChronic DiseaseHard palatebusinessMouth DiseasesOral medicineErythroplakialcsh:Q1-390
researchProduct

Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized…

2012

Several prognostic factors for the outcome after allogeneic hematopoietic stem-cell transplant (HSCT) from matched unrelated donors have been postulated from registry data; however, data from randomized trials are lacking. We present analyses on the effects of patient-related, donor-related, and treatment-related prognostic factors on acute GVHD (aGVHD), chronic GVHD (cGVHD), relapse, nonrelapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) in a randomized, multicenter, open-label, phase III trial comparing standard graft-versus-host-disease (GVHD) prophylaxis with and without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative co…

MaleOncologyTransplantation Conditioningmedicine.medical_treatmentMedizinGraft vs Host DiseaseHematopoietic stem cell transplantationSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled trialHLA Antigenslawimmune system diseaseshemic and lymphatic diseasesAllogeneic hematopoietic stem-cell transplantationMedicineProspective StudiesProspective cohort studyHematologyHistocompatibility TestingAge FactorsHematopoietic Stem Cell TransplantationHematologyMiddle Aged3. Good healthSurvival Ratesurgical procedures operative030220 oncology & carcinogenesisAcute DiseaseFemaleUnrelated DonorsAdultmedicine.medical_specialtyAllogeneic transplantationAdolescentGraft-versus-host-disease prophylaxis03 medical and health sciencesInternal medicineHumansTransplantation HomologousHLA-matchingSurvival rateAntilymphocyte SerumTransplantationbusiness.industryMyeloablative AgonistsTransplantationChronic DiseaseImmunologyTransplantation Conditioningbusiness030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct

The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Anal…

2021

T-cell epitope matching according to the TCE3 algorithm classifies HLA-DPB1 mismatches in permissive and non-permissive. This classification has been shown to be predictive for mortality and acute GvHD (aGvHD) events in large international cohorts. We retrospectively genotyped HLA-DPB1 in 3523 patients transplanted in Germany between 2000 and 2014 and in their unrelated donors using an Illumina amplicon-NGS based assay. Aim of the study was to evaluate DP-compatibility beyond the established TCE3 algorithm by assessing the combined effect of several DP-mismatch parameters on post-transplant outcome. We implemented an extended DP-mismatch assessment model where TCE3, DP allotype expression w…

MalePermissivenessOncologyGraft vs host diseaseEpitopes T-LymphocyteGraft vs Host DiseaseKaplan-Meier Estimategraft-versus-host-disease0302 clinical medicineGermanyImmunology and AllergyChild3' Untranslated RegionsHLA-DP beta-ChainsBone Marrow TransplantationOriginal Research0303 health sciencesHistocompatibility TestingIncidenceStem cell transplantationMiddle AgedAllograftsAllotype3. Good healthHLA-DPB1Child PreschoolHistocompatibility030220 oncology & carcinogenesisFemaleUnrelated Donorslcsh:Immunologic diseases. AllergyAdultRiskmedicine.medical_specialtyAdolescentImmunologyGraft vs Leukemia EffectHuman leukocyte antigenPolymorphism Single Nucleotidestem cell transplantationRelapse free survivalLymphocyte DepletionYoung Adult03 medical and health sciencesInternal medicinemedicineHumansTransplantat-Wirt-Reaktionddc:610PermissivePeriphere StammzellentransplantationAllelesAgedRetrospective Studies030304 developmental biologyPeripheral Blood Stem Cell TransplantationHLA-DPB1Donor selectionbusiness.industryInfant NewbornModels ImmunologicalInfantmedicine.diseaseGraft-versus-host diseaseHLA-DPB1-permissivenessHLA-DPB1 expressionlcsh:RC581-607businessFrontiers in Immunology
researchProduct